Bayer : Low valuation remains justified given ongoing uncertainties
>CMD did not deliver what many investors had hoped for - In recent months, many hopes were pinned on the CMD on 5 March, which was expected to provide more clarity on Bayer's strategic direction. In particular, how to tackle the high level of debt that currently limits financial flexibility, e.g. to invest in the weakening pharma pipeline. At the same time, hopes for a major strategic move, such as the separation of the Consumer Health (CH) division, had already faded...Bayer is a life sciences group based in Germany. Co.'s operations are organized along three divisions: Pharmaceuticals (engaged in prescription pharmaceuticals for cardiology and women's healthcare); Consumer Health (engaged in non-prescription products in dermatology, dietary supplement, analgesic, gastrointestinal, allergy, cold and flu, foot care, sun protection and cardiovascular risk prevention categories); and CropScience (engaged in the development of seeds and plant traits; crop protection; and for gardens, the green industry and non-agricultural pest control). Co. also maintains an Animal Health business unit engaged in the development of products for farm and companion animals.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.